Hygiena 2014, 59(4):184-189 | DOI: 10.21101/hygiena.a1292

Health Aspects of Thermal Food Processing

Bohumil Turek1, Petr Šíma2, Vladimír Bencko3
1 Společnost pro výživu, Praha
2 Mikrobiologický ústav v. v. i., AV ČR, Praha
3 Ústav hygieny a epidemiologie 1. LF UK a VFN, Praha

The recent results of research in the field of nutritional immunology have a wide impact on health protection and promotion-related activities. There is a great deal of evidence showing that the inadequate or lowered nutritional intake is reflected in both protein-energetic malnutrition and immune system disorders. A growing number of in vitro/in vivo experimental and clinical studies documents that the products of non-enzymatic reactions formed during technological and culinary processing of food may play a major role in the emergence and global spread of chronic non-communicable diseases. Evidence mainly points to the pathogenic role of advanced glycation end products (AGE), advanced lipoxidation end products (ALE), and advanced oxidation protein products (AOPP), which represent the most important dietary compounds that accumulate within the internal milieu of an organism over a whole life span. Currently, these factors are regarded as one of a row of causations with strong negative influence on health and the most frequent causative agents of increasing chronic disease burden in all countries which adopt a "westernized lifestyle".

Keywords: chronic non-communicable diseases - etiology, processed foods, Advanced Glycation End products (AGE), Advanced Lipoxidation End products (ALE), Advanced Oxidation Protein Products (AOPP)

Received: February 2014; Accepted: October 22, 2014; Published: December 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Turek B, Šíma P, Bencko V. Health Aspects of Thermal Food Processing. Hygiena. 2014;59(4):184-189. doi: 10.21101/hygiena.a1292.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell. 1997 Oct 31;91(3):295-8. Go to original source... Go to PubMed...
    2. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045. Go to original source... Go to PubMed...
    3. Lenardo MJ, Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell. 1989 Jul 28;58(2):227-9. Go to original source... Go to PubMed...
    4. Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia. 1998 Dec;41(12):1435-41. Go to original source... Go to PubMed...
    5. Šíma P. Chronický únavový syndrom. Interní Med Praxi. 2010;12(9):419-23.
    6. Šíma P, Turek B, Bencko V. Nutriční imunologie: modulace imunity složkami nutrice. Prakt Lék. 2013;93(4):158-62.
    7. Cerami A, Vlassara H, Brownlee M. Glucose and aging. Sci Am. 1987 May;256(5):90-6. Go to original source... Go to PubMed...
    8. Bengmark S. Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN J Parenter Enteral Nutr. 2006 Jan-Feb;30(1):45-51. Go to original source... Go to PubMed...
    9. Pokupec R, Kalauz M, Turk N, Turk Z. Advanced glycation endproducts in human diabetic and non-diabetic cataractous lenses. Graefes Arch Clin Exp Ophthalmol. 2003 May;241(5):378-84. Go to original source... Go to PubMed...
    10. Rahbar S. An abnormal hemoglobin in red cells of diabetics. Clin Chim Acta. 1968 Oct;22(2):296-8. Go to original source...
    11. Rahbar S. The discovery of glycated haemoblobin: a major event in the study of nonenzymatic chemistry in biological systems. Ann N Y Acad Sci. 2005 Jun;1043:9-19. Go to original source... Go to PubMed...
    12. Jentzsch AM, Bachmann H, Fürst P, Biesalski HK. Improved analysis of malondialdehyde in human body fluids. Free Radic Biol Med. 1996;20(2):251-6. Go to original source...
    13. Chavakis T, Bierhaus A, Nawroth PP. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect. 2004 Nov;6(13):1219-25. Go to original source... Go to PubMed...
    14. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442 Go to original source... Go to PubMed...
    15. Svačina Š. Metabolický syndrom a diabetes 2. typu. In: Svačina Š. Prevence diabetu a jeho komplikací. Praha: Triton; 2008. p. 19-31.
    16. Maeshima T, Honda K, Chikazawa M, Shibata T, Kawai Y, Akagawa M, et al. Quantitative analysis of acrolein-specific adducts generated during lipid peroxidation-modification of proteins in vitro: identification of N(tau)-(3-propanal) histidine as the major adduct. Chem Res Toxicol. 2012 Jul 16;25(7):1384-92. Go to original source... Go to PubMed...
    17. Agalou S, Ahmed N, Dawnay A, Thornalley PJ. Removal of advanced glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis. Biochem Soc Trans. 2003 Dec;31(Pt 6):1394-6. Go to original source...
    18. Bengmark S. Advanced glycation and lipoxidation end products-amplifiers of inflammation: the role of food. JPEN J Parenter Enteral Nutr. 2007 Sept-Oct;31(5):430-40. Go to original source... Go to PubMed...
    19. Bucala R. Lipid and lipoprotein modification by advanced glycosylation end-products: role in atherosclerosis. Exp Physiol. 1997 Mar;82(2):327-37. Go to original source... Go to PubMed...
    20. Selmeci L. Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome? Free Radic Res. 2011 Oct;45(10):1115-23. Go to original source... Go to PubMed...
    21. Kalousová M, Škrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res. 2002;51(6):597-604. Go to original source...
    22. Castellani R, Smith MA, Richey PJ, Petty G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res. 1996 Oct 21;737(1-2):195-200. Go to original source... Go to PubMed...
    23. Ma L, Nicholson LF. Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus. Brain Res. 2004 Aug 20;1018(1):10-7. Go to original source... Go to PubMed...
    24. Frey J. Bovine spongiform encephalopathy: are the cows mad or full of carbohydrates. Clin Chem Lab Med. 2002 Feb;40(2):101-3. Go to original source... Go to PubMed...
    25. Vlassara H, Palace MR. Diabetes and advanced glycation end products. J Intern Med. 2002 Feb;251(2):87-101. Go to original source... Go to PubMed...
    26. Qin Q, Niu J, Wang Z, Xu W, Qiao Z, Gu Y. Heparanase induced by advanced glycation end products (AGEs) promotes macrophage migration involving RAGE and PI3K/AKT pathway. Cardiovasc Diabetol. 2013 Feb 26;12:37. Go to original source... Go to PubMed...
    27. Xu D, Young J, Song, D, Esko JD. Heparan sulphate is essential for high mobility group protein 1 (HMGB1) signaling by the receptor for advanced glycation end products (RAGE). J Biol Chem. 2011 Dec 2;286(48):41736-44. Go to original source... Go to PubMed...
    28. Rouhiainen A, Kuja-Panula J, Tumova S, Rauvala H. RAGEmediated cell signaling. Methods Mol Biol. 2013;963:239-63. Go to original source... Go to PubMed...
    29. Lin L. RAGE on the Toll Road? Cell Mol Immunol. 2006 Oct;3(5):351-8.
    30. Šíma P, Turek B, Bencko V. Prozánětové složky nutrice jako jedna z příčin rostoucí incidence chronických nesdělných nemocí? Prakt Lék. 2014;94(1):32-7.
    31. Osawa T, Kato Y. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. Ann N Y Acad Sci. 2005 Jun;1043:440-51. Go to original source... Go to PubMed...
    32. Hansen SH. The role of taurine in diabetes and the development of diabetic compplications. Diabetes Metab Res Rev. 2001 Sep-Oct;17(5):330-46. Go to original source... Go to PubMed...
    33. Gorelik S, Ligumsky M, Kohen R, Kanner J. A novel function of red wine polyphenols in humans: prevention of absorption of cytotoxic lipid peroxidation products. FASEB J. 2008 Jan;22(1):41-6. Go to original source... Go to PubMed...
    34. Nandhini AT, Thirunavukkarasu V, Anuradha CV. Stimulation of glucose utilization and inhibition of protein glycation and AGE products by taurine. Acta Physiol Scand. 2004 Jul;181(3):297-303. Go to original source... Go to PubMed...
    35. Hille-Rehfeld A. Carnosine - an endogenous antioxidant and tissue protective factor. Med Monatsschr Pharm. 2006 Sep;29(9):337-8. (In German.) Go to PubMed...
    36. Lee SJ, Lee KW. Protective effect of (-)-epigallocatechin gallate against advanced glycation endproducts-induced injury in neuronal cells. Biol Pharm Bull. 2007 Aug;30(8):1369-73. Erratum in: Biol Pharm Bull. 2007 Dec;30(12):2412. Go to original source... Go to PubMed...
    37. Biesalski HK. Polyphenols and inflammation: basic interactions. Curr Opin Clin Nutr Metab Care. 2007 Nov;10(6):724-8. Go to original source... Go to PubMed...
    38. Roszkowski K, Ko HL, Beuth J, Ohshima Y, Roszkowski W, Jeljaszewicz J, et al. Intestinal microflora of BALB/c-mice and function of local immune cells. Zentralbl Bakteriol Microbiol Hyg A. 1988 Nov;270(1-2):270-9. Go to original source...
    39. Pulverer G, Beuth J, Roszkowski W, Burrichter H, Roszkowski K, Yassin A, et al. Bacteria of human physiological microflora liberate immunomodulating peptides. Zentralbl Bakteriol. 1990 Apr;272(4):467-76. Go to original source...
    40. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens. 2003 Jan;21(1):3-12. Go to original source... Go to PubMed...

    Return to the content